Curbside Consultation in IBD
49 Clinical Questions
2nd Edition
Published on 15. June 2014
Book
Paperback/Softback
272 pages
978-1-61711-034-4 (ISBN)
Description
Curbside Consultation in IBD: 49 Clinical Questions has been updated into a Second Edition!
The Second Edition contains new questions and is completely updated!
Are you looking for concise, practical answers to questions that are often left unanswered by traditional inflammatory bowel disease (IBD) references? Are you seeking brief, evidence-based and updated advice for complicated cases or complications? Curbside Consultation in IBD: 49 Clinical Questions, Second Edition provides quick and direct answers to the thorny questions commonly posed during a "curbside consultation" between colleagues.
Dr. David T. Rubin, Dr. Sonia Friedman, and Dr. Francis A. Farraye are joined by a world-class group of contributors on the Second Edition, which offers expert advice, preferences, and opinions on tough clinical questions commonly associated with IBD. The unique Q&A format provides quick access to current information related to IBD with the simplicity of a conversation between two colleagues. Numerous images, diagrams, and references are included to better illustrate IBD.
Some of the questions that are answered inside the Second Edition include:
How can I clarify the diagnosis in my patient with indeterminate colitis?
What is the role of concomitant immunomodulators with biologic use in IBD?
When in the treatment algorithm should methotrexate be considered for Crohn's disease? Is there a role for low-dose methotrexate in the prevention of immunogenicity?
How should we be using fecal markers such as lactoferrin and calprotectin in our patients?
Should I use chromoendoscopy in my surveillance colonoscopy in IBD? How and which agent?
What is the updated approach to antimetabolites and biologic therapy in IBD and pregnancy?
When should I consider anti-integrin therapy for my patient with IBD?
Curbside Consultation in IBD: 49 Clinical Questions, Second Edition has been updated with new questions and answers, and has chapters organized by topic. The format provides information that high-volume clinicians will appreciate, and yet is basic enough for trainees and students.
The Second Edition contains new questions and is completely updated!
Are you looking for concise, practical answers to questions that are often left unanswered by traditional inflammatory bowel disease (IBD) references? Are you seeking brief, evidence-based and updated advice for complicated cases or complications? Curbside Consultation in IBD: 49 Clinical Questions, Second Edition provides quick and direct answers to the thorny questions commonly posed during a "curbside consultation" between colleagues.
Dr. David T. Rubin, Dr. Sonia Friedman, and Dr. Francis A. Farraye are joined by a world-class group of contributors on the Second Edition, which offers expert advice, preferences, and opinions on tough clinical questions commonly associated with IBD. The unique Q&A format provides quick access to current information related to IBD with the simplicity of a conversation between two colleagues. Numerous images, diagrams, and references are included to better illustrate IBD.
Some of the questions that are answered inside the Second Edition include:
How can I clarify the diagnosis in my patient with indeterminate colitis?
What is the role of concomitant immunomodulators with biologic use in IBD?
When in the treatment algorithm should methotrexate be considered for Crohn's disease? Is there a role for low-dose methotrexate in the prevention of immunogenicity?
How should we be using fecal markers such as lactoferrin and calprotectin in our patients?
Should I use chromoendoscopy in my surveillance colonoscopy in IBD? How and which agent?
What is the updated approach to antimetabolites and biologic therapy in IBD and pregnancy?
When should I consider anti-integrin therapy for my patient with IBD?
Curbside Consultation in IBD: 49 Clinical Questions, Second Edition has been updated with new questions and answers, and has chapters organized by topic. The format provides information that high-volume clinicians will appreciate, and yet is basic enough for trainees and students.
Reviews / Votes
"This is an informative, current, state-of-the-art book on inflammatory bowel disease that is an essential item for every clinician in training and every academic library."- Vincent F. Carr, DO, MSA, FACC, FACP, Uniformed Services University of the Health Sciences, Doody's Review Service
More details
Edition
2nd Revised edition
Language
English
Place of publication
United States
Publishing group
Taylor & Francis Inc
Target group
Professional and scholarly
Edition type
Revised edition
Dimensions
Height: 254 mm
Width: 178 mm
Weight
658 gr
ISBN-13
978-1-61711-034-4 (9781617110344)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
New editions
David T. Rubin | Sonia Friedman | Francis A. Farraye
Curbside Consultation in IBD
49 Clinical Questions
Book
10/2021
3rd Edition
SLACK Incorporated
€183.50
Shipment within 3-4 weeks
Content
Dedication
Acknowledgments
About the Editors
Contributing Authors
Preface
Foreword by William J. Tremaine, MD
Introduction
Section I Diagnosis
Question 1 How Can We Assess Prognosis in Crohn's Disease?
Marla C. Dubinsky, MD
Question 2 How Can I Clarify the Diagnosis in My Patient With Indeterminate Colitis?
William J. Tremaine, MD
Question 3 How Do You Evaluate Small Bowel Crohn's Disease? How Do You Assess Response to Therapy?
Talia Zenlea, MD and Adam Cheifetz, MD
Question 4 How Do I Choose Between Computed Tomography and Magnetic Resonance Imaging for My Crohn's Disease Patients? Is There Still a Role for Barium?
David H. Bruining, MD
Question 5 What Is the Updated Role of Capsule Endoscopy in Crohn's Disease?
Neal C. Patel, MD; Rafiul S. Islam, MD; and Jonathan A. Leighton, MD
Question 6 What Necessary Testing Should Be Performed Before Initiating Biologic Therapy?
Maria Laura Annunziata, MD, PhD and David T. Rubin, MD
Question 7 How Should We Be Using C-Reactive Protein and Fecal Markers, Such as Lactoferrin or Calprotectin, in Our Patients?
Severine Vermeire, MD, PhD; Marc Ferrante, MD, PhD; and Paul Rutgeerts, MD, PhD
Question 8 My Patient on Tumor Necrosis Factor Alpha Therapy Has a Rash. What Should I Do?
Abrar A. Qureshi, MD and Andrew C. Walls, MD
Question 9 My Crohn's Disease Patient Is Complaining of Joint Pain. What Should I Do?
Richard Keating, MD
Question 10 My Patient With an Ileo Pouch-Anal Anastomosis Has Developed Diarrhea and Urgency. What Is the Differential Diagnosis, and How Should I Evaluate Him? What Is the Significance of Pre-pouch Ileitis?
Simon McLaughlin, MBBS, MD(Res)
Question 11 How Often Does Celiac Disease Coexist With Inflammatory Bowel Disease?
Ciaran Kelly, MD and Toufic Kabbani, MD
Section II Medical Treatment
Question 12 What Endpoints Should We Aim for in Inflammatory Bowel Disease Medical Therapy?
Marc Ferrante, MD, PhD and Gert Van Assche, MD, PhD
Question 13 Is There Ever a Time to Switch to 5-Aminosalicylic Acids in Ulcerative Colitis?
Stephen B. Hanauer, MD
Question 14 Which Therapies Are Steroid Sparing in Crohn's Disease and Ulcerative Colitis? How Should I Manage a Steroid Dependent Patient?
David Kotlyar, MD; Wojciech Blonski, MD, PhD; Joseph Gorodenker, MD; and Gary R. Lichtenstein, MD
Question 15 What Is the Role of Concomitant Immunomodulators With Biologic Use in Inflammatory Bowel Disease?
Russell D. Cohen, MD
Question 16 How Do You Optimize Therapy With Thiopurines?
Antony B. Friedman, MBBS and Miles P. Sparrow, MBBS
Question 17 How Long Do You Wait Before Declaring Treatment Failure With Azathioprine/6-Mercaptopurine, and Do You Ever Consider Stopping Therapy With These Agents After a Period of Time?
Julian Panes, MD, PhD and Elena Ricart, MD, PhD
Question 18 Which Patients Might Be Better for a "Top-Down" Approach (Using Anti-Tumor Necrosis Factor Therapy Before Steroids or Proven Failure of Oral Thiopurines)? Which Patients Should Be Started on Dual Therapy (Immunomodulator and Anti-Tumor Necrosis Factor)?
Sonia Friedman, MD
Question 19 When Is It Appropriate to Switch to Another Biologic Therapy?
David T. Rubin, MD and Adam E. Mikolajczyk, MD
Question 20 What Are the Risks of Biologic Therapies, and How Do You Communicate Them to Patients?
L. Campbell Levy, MD and Corey A. Siegel, MD
Question 21 When Should I Consider Anti-Integrin Therapy for My Patient With Inflammatory Bowel Disease? What Is the Updated Understanding of Progressive Multifocal Leukoencephalopathy and John Cunningham Virus Testing?
Nitsan Maharshak, MD and Scott E. Plevy, MD
Question 22 Is It Ever Appropriate to Stop Anti-Tumor Necrosis Factor in a Stable Patient?
Edouard Louis, MD, PhD
Question 23 When in the Treatment Algorithm Should Methotrexate Be Considered for Treatment of Crohn's Disease? Is There a Role for Low-Dose Methotrexate for Immunogenicity Purposes?
Hilary Steinhart, MD
Question 24 What Are the Relative Benefits of Cyclosporine or Infliximab in Severe Ulcerative Colitis? How Do You Choose Between the Two Options?
Seamus J. Murphy, MD, PhD and Asher Kornbluth, MD
Question 25 How Do You Treat Pouchitis? What Do You Do for Recurrent or Refractory Pouchitis?
Bo Shen, MD
Question 26 What Is the Role of Probiotics in My Patients With Inflammatory Bowel Disease?
Fergus Shanahan, MD
Question 27 What Is Your First-Line Approach to the Diagnosis and Treatment of Patients With Perianal Crohn's Disease?
Natalie Nesmith, MD and David A. Schwartz, MD
Question 28 How Do You Handle an Inflammatory Bowel Disease Patient With Clostridium difficile Infection?
David G. Binion, MD
Question 29 My Patient Has Primary Sclerosing Cholangitis and Ulcerative Colitis. Is There a Role for Ursodeoxycholic Acid Anymore?
Elizabeth J. Carey, MD and Keith D. Lindor, MD
Question 30 What Is the Optimal Management of Ulcerative Proctosigmoiditis?
Douglas C. Wolf, MD
Question 31 My Patient Has a History of Breast Cancer and Is in Remission From That Condition. She Also Has Crohn's Disease. Can I Use Azathioprine or Infliximab to Treat Her? What if There Is a Family History of Lymphoma or Leukemia? Should That Influence Management?
Remo Panaccione, MD
Question 32 My Patient Recently Had a Sigmoid Colon Resection for Diverticulitis. The Pathology Report Read "Chronic Colitis." Is Diverticular-Associated Colitis a Subset of Inflammatory Bowel Disease, and Does My Patient Need Any Medical Therapy to Prevent Recurrence of Colitis?
Matthew J. Hamilton, MD and Sonia Friedman, MD
Question 33 What Is the Best Medical Therapy for Inflammatory Bowel Disease in Elderly Patients? Are Anti-Tumor Necrosis Factors Safe in This Patient Population?
Darrell S. Pardi, MD and Edward V. Loftus Jr, MD
Section III Surgical Treatment
Question 34 My Patient With Crohn's Disease Has an Ileal Abscess. What Is the Appropriate Management and Timing of Medical and Surgical Therapies?
Linda A. Feagins, MD and Sunanda V. Kane, MD
Question 35 What Are the Latest Robotic and Laparoscopic Approaches for Inflammatory Bowel Disease Surgery?
I. Emre Gorgun, MD and Feza H. Remzi, MD
Question 36 How Should I Treat My Crohn's Disease Patient After an Ileocecectomy and Primary Anastomosis?
Miguel Regueiro, MD
Question 37 How Does Perioperative Immune Suppression Affect Surgical Outcomes in Inflammatory Bowel Disease?
Liliana Bordeianou, MD and Richard Hodin, MD
Section IV Cancer/Infection Prevention
Question 38 Should I Use Chromoendoscopy in My Surveillance Colonoscopy in Inflammatory Bowel Disease? How and Which Agent? Would Narrow-band Imaging Be an Alternative for This?
David T. Rubin, MD and Jami A. Kinnucan, MD
Question 39 Can We Follow Flat Low-Grade Dysplasia? Is Any Dysplasia Really Flat or Just a Spectrum of Depth and Size?
Arun Swaminath, MD and Thomas Ullman, MD
Question 40 How Do You Screen and Survey for Dysplasia in Crohn's Disease Patients? Can You Perform Segmental Resection in Crohn's Disease Patients With Dysplasia?
Sonia Friedman, MD
Question 41 What Is the Risk of Skin Cancer in Inflammatory Bowel Disease? What Should We Recommend to Our Patients?
Millie D. Long, MD
Question 42 How Do You Approach Polypoid Lesions in Patients With Inflammatory Bowel Disease?
Fernando Velayos, MD and Francis A. Farraye, MD, MSc
Question 43 What Is the Most Effective Strategy to Promote Smoking Cessation in Patients With Crohn's Disease?
Janani Deffendall, PhD and Andrea King, PhD
Question 44 What Is the Risk of Lymphoma With Antimetabolites and Anti-Tumor Necrosis Factor Agents?
Peter Irving, MD
Question 45 What Is the Updated Approach to Antimetabolites and Biologic Therapy in Inflammatory Bowel Disease and Pregnancy?
Uma Mahadevan, MD
Question 46 Which Vaccines Should I Recommend for My Inflammatory Bowel Disease Patients, and When Should I Give Them?
Sharmeel K. Wasan, MD and Francis A. Farraye, MD, MSc
Question 47 Which Inflammatory Bowel Disease Patients Should I Screen for Osteoporosis? Should I Also Screen for Vitamin D Deficiency?
Hannah L. Miller, MD and Francis A. Farraye, MD, MSc
Question 48 What Is the Role of Diet in the Treatment of Inflammatory Bowel Disease? How Do I Discuss This With My Patients?
Tracie M. Dalessandro, MS, RD, CDN
Question 49 What Advice Should I Give the Inflammatory Bowel Disease Patient Who Is Traveling?
Kim L. Isaacs, MD, PhD
Financial Disclosures
Index
Acknowledgments
About the Editors
Contributing Authors
Preface
Foreword by William J. Tremaine, MD
Introduction
Section I Diagnosis
Question 1 How Can We Assess Prognosis in Crohn's Disease?
Marla C. Dubinsky, MD
Question 2 How Can I Clarify the Diagnosis in My Patient With Indeterminate Colitis?
William J. Tremaine, MD
Question 3 How Do You Evaluate Small Bowel Crohn's Disease? How Do You Assess Response to Therapy?
Talia Zenlea, MD and Adam Cheifetz, MD
Question 4 How Do I Choose Between Computed Tomography and Magnetic Resonance Imaging for My Crohn's Disease Patients? Is There Still a Role for Barium?
David H. Bruining, MD
Question 5 What Is the Updated Role of Capsule Endoscopy in Crohn's Disease?
Neal C. Patel, MD; Rafiul S. Islam, MD; and Jonathan A. Leighton, MD
Question 6 What Necessary Testing Should Be Performed Before Initiating Biologic Therapy?
Maria Laura Annunziata, MD, PhD and David T. Rubin, MD
Question 7 How Should We Be Using C-Reactive Protein and Fecal Markers, Such as Lactoferrin or Calprotectin, in Our Patients?
Severine Vermeire, MD, PhD; Marc Ferrante, MD, PhD; and Paul Rutgeerts, MD, PhD
Question 8 My Patient on Tumor Necrosis Factor Alpha Therapy Has a Rash. What Should I Do?
Abrar A. Qureshi, MD and Andrew C. Walls, MD
Question 9 My Crohn's Disease Patient Is Complaining of Joint Pain. What Should I Do?
Richard Keating, MD
Question 10 My Patient With an Ileo Pouch-Anal Anastomosis Has Developed Diarrhea and Urgency. What Is the Differential Diagnosis, and How Should I Evaluate Him? What Is the Significance of Pre-pouch Ileitis?
Simon McLaughlin, MBBS, MD(Res)
Question 11 How Often Does Celiac Disease Coexist With Inflammatory Bowel Disease?
Ciaran Kelly, MD and Toufic Kabbani, MD
Section II Medical Treatment
Question 12 What Endpoints Should We Aim for in Inflammatory Bowel Disease Medical Therapy?
Marc Ferrante, MD, PhD and Gert Van Assche, MD, PhD
Question 13 Is There Ever a Time to Switch to 5-Aminosalicylic Acids in Ulcerative Colitis?
Stephen B. Hanauer, MD
Question 14 Which Therapies Are Steroid Sparing in Crohn's Disease and Ulcerative Colitis? How Should I Manage a Steroid Dependent Patient?
David Kotlyar, MD; Wojciech Blonski, MD, PhD; Joseph Gorodenker, MD; and Gary R. Lichtenstein, MD
Question 15 What Is the Role of Concomitant Immunomodulators With Biologic Use in Inflammatory Bowel Disease?
Russell D. Cohen, MD
Question 16 How Do You Optimize Therapy With Thiopurines?
Antony B. Friedman, MBBS and Miles P. Sparrow, MBBS
Question 17 How Long Do You Wait Before Declaring Treatment Failure With Azathioprine/6-Mercaptopurine, and Do You Ever Consider Stopping Therapy With These Agents After a Period of Time?
Julian Panes, MD, PhD and Elena Ricart, MD, PhD
Question 18 Which Patients Might Be Better for a "Top-Down" Approach (Using Anti-Tumor Necrosis Factor Therapy Before Steroids or Proven Failure of Oral Thiopurines)? Which Patients Should Be Started on Dual Therapy (Immunomodulator and Anti-Tumor Necrosis Factor)?
Sonia Friedman, MD
Question 19 When Is It Appropriate to Switch to Another Biologic Therapy?
David T. Rubin, MD and Adam E. Mikolajczyk, MD
Question 20 What Are the Risks of Biologic Therapies, and How Do You Communicate Them to Patients?
L. Campbell Levy, MD and Corey A. Siegel, MD
Question 21 When Should I Consider Anti-Integrin Therapy for My Patient With Inflammatory Bowel Disease? What Is the Updated Understanding of Progressive Multifocal Leukoencephalopathy and John Cunningham Virus Testing?
Nitsan Maharshak, MD and Scott E. Plevy, MD
Question 22 Is It Ever Appropriate to Stop Anti-Tumor Necrosis Factor in a Stable Patient?
Edouard Louis, MD, PhD
Question 23 When in the Treatment Algorithm Should Methotrexate Be Considered for Treatment of Crohn's Disease? Is There a Role for Low-Dose Methotrexate for Immunogenicity Purposes?
Hilary Steinhart, MD
Question 24 What Are the Relative Benefits of Cyclosporine or Infliximab in Severe Ulcerative Colitis? How Do You Choose Between the Two Options?
Seamus J. Murphy, MD, PhD and Asher Kornbluth, MD
Question 25 How Do You Treat Pouchitis? What Do You Do for Recurrent or Refractory Pouchitis?
Bo Shen, MD
Question 26 What Is the Role of Probiotics in My Patients With Inflammatory Bowel Disease?
Fergus Shanahan, MD
Question 27 What Is Your First-Line Approach to the Diagnosis and Treatment of Patients With Perianal Crohn's Disease?
Natalie Nesmith, MD and David A. Schwartz, MD
Question 28 How Do You Handle an Inflammatory Bowel Disease Patient With Clostridium difficile Infection?
David G. Binion, MD
Question 29 My Patient Has Primary Sclerosing Cholangitis and Ulcerative Colitis. Is There a Role for Ursodeoxycholic Acid Anymore?
Elizabeth J. Carey, MD and Keith D. Lindor, MD
Question 30 What Is the Optimal Management of Ulcerative Proctosigmoiditis?
Douglas C. Wolf, MD
Question 31 My Patient Has a History of Breast Cancer and Is in Remission From That Condition. She Also Has Crohn's Disease. Can I Use Azathioprine or Infliximab to Treat Her? What if There Is a Family History of Lymphoma or Leukemia? Should That Influence Management?
Remo Panaccione, MD
Question 32 My Patient Recently Had a Sigmoid Colon Resection for Diverticulitis. The Pathology Report Read "Chronic Colitis." Is Diverticular-Associated Colitis a Subset of Inflammatory Bowel Disease, and Does My Patient Need Any Medical Therapy to Prevent Recurrence of Colitis?
Matthew J. Hamilton, MD and Sonia Friedman, MD
Question 33 What Is the Best Medical Therapy for Inflammatory Bowel Disease in Elderly Patients? Are Anti-Tumor Necrosis Factors Safe in This Patient Population?
Darrell S. Pardi, MD and Edward V. Loftus Jr, MD
Section III Surgical Treatment
Question 34 My Patient With Crohn's Disease Has an Ileal Abscess. What Is the Appropriate Management and Timing of Medical and Surgical Therapies?
Linda A. Feagins, MD and Sunanda V. Kane, MD
Question 35 What Are the Latest Robotic and Laparoscopic Approaches for Inflammatory Bowel Disease Surgery?
I. Emre Gorgun, MD and Feza H. Remzi, MD
Question 36 How Should I Treat My Crohn's Disease Patient After an Ileocecectomy and Primary Anastomosis?
Miguel Regueiro, MD
Question 37 How Does Perioperative Immune Suppression Affect Surgical Outcomes in Inflammatory Bowel Disease?
Liliana Bordeianou, MD and Richard Hodin, MD
Section IV Cancer/Infection Prevention
Question 38 Should I Use Chromoendoscopy in My Surveillance Colonoscopy in Inflammatory Bowel Disease? How and Which Agent? Would Narrow-band Imaging Be an Alternative for This?
David T. Rubin, MD and Jami A. Kinnucan, MD
Question 39 Can We Follow Flat Low-Grade Dysplasia? Is Any Dysplasia Really Flat or Just a Spectrum of Depth and Size?
Arun Swaminath, MD and Thomas Ullman, MD
Question 40 How Do You Screen and Survey for Dysplasia in Crohn's Disease Patients? Can You Perform Segmental Resection in Crohn's Disease Patients With Dysplasia?
Sonia Friedman, MD
Question 41 What Is the Risk of Skin Cancer in Inflammatory Bowel Disease? What Should We Recommend to Our Patients?
Millie D. Long, MD
Question 42 How Do You Approach Polypoid Lesions in Patients With Inflammatory Bowel Disease?
Fernando Velayos, MD and Francis A. Farraye, MD, MSc
Question 43 What Is the Most Effective Strategy to Promote Smoking Cessation in Patients With Crohn's Disease?
Janani Deffendall, PhD and Andrea King, PhD
Question 44 What Is the Risk of Lymphoma With Antimetabolites and Anti-Tumor Necrosis Factor Agents?
Peter Irving, MD
Question 45 What Is the Updated Approach to Antimetabolites and Biologic Therapy in Inflammatory Bowel Disease and Pregnancy?
Uma Mahadevan, MD
Question 46 Which Vaccines Should I Recommend for My Inflammatory Bowel Disease Patients, and When Should I Give Them?
Sharmeel K. Wasan, MD and Francis A. Farraye, MD, MSc
Question 47 Which Inflammatory Bowel Disease Patients Should I Screen for Osteoporosis? Should I Also Screen for Vitamin D Deficiency?
Hannah L. Miller, MD and Francis A. Farraye, MD, MSc
Question 48 What Is the Role of Diet in the Treatment of Inflammatory Bowel Disease? How Do I Discuss This With My Patients?
Tracie M. Dalessandro, MS, RD, CDN
Question 49 What Advice Should I Give the Inflammatory Bowel Disease Patient Who Is Traveling?
Kim L. Isaacs, MD, PhD
Financial Disclosures
Index